BioMarin, Alliant enter licensing agreement for Orapred for asthma in children

By Lisa Kerner

Erie, Pa., March 15 - BioMarin Pharmaceutical Inc. and Alliant Pharmaceuticals, Inc. have entered into a licensing and acquisition agreement regarding exclusive North American rights to the Orapred (prednisolone sodium phosphate oral solution) product line, including Orapred ODT (prednisolone sodium phosphate orally disintegrating tablets).

Orapred liquid prednisolone sodium phosphate is used to treat exacerbations of asthma and other inflammatory diseases and conditions in children.

Under the agreement, BioMarin will receive payments and royalties based on product approvals, launch and sales. The company will also retain commercial rights outside of North America.

"This partnership aligns well with both BioMarin and Alliant's business strategy," BioMarin chief executive officer Jean-Jacques Bienaime said in the release.

"Orapred no longer fits well with our core business of developing and commercializing novel products for serious genetic and metabolic diseases."

Orapred ODT is expected to commercially launch in the United States during the second half of 2006, according to a company news release. BioMarin filed a New Drug Application for Orapred ODT with the Food and Drug Administration in August 2005.

BioMarin, based in Novato, Calif., develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

Alliant is a privately held specialty pharmaceutical company located in Alpharetta, Ga.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.